Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00215943 · MORE INFO

Limitations, agreements, and source contact

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) · Source last updated 2014-04-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Target accrual for planned analysis (176) was not met. Principal Investigator (PI) determined study must close due to changes in the management of newly diagnosed myeloma (emergence of new drugs, more effective regimens).
point Of Contact
email
melissa.alsina@moffitt.org
organization
H. Lee Moffitt Cancer Center and Research Institute
phone
813-745-6886
title
Melissa Alsina, M.D.
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Target accrual for planned analysis (176) was not met. Principal Investigator (PI) determined study must close due to changes in the management of newly diagnosed myeloma (emergence of new drugs, more effective regimens).
point Of Contact
email
melissa.alsina@moffitt.org
organization
H. Lee Moffitt Cancer Center and Research Institute
phone
813-745-6886
title
Melissa Alsina, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice